ASCO: AI Training Improves Accuracy of HER2 Immunohistochemistry Scoring

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 30, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, May 30, 2025 -- Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring in patients with breast cancer, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

David Mulder, from Mindpeak GmbH in Hamburg, Germany, and colleagues developed a training platform for AI-supported digital HER2 IHC assessment of breast cancer samples for pathologists. One hundred five pathologists participated in masterclass sessions, assessing 20 digital HER2 IHC stained breast cancer cases, both with and without AI assistance. The masterclasses included exam A, a lecture on HER IHC scoring, exam B, discussion of results, and AI-assisted exam C.

The researchers found that pathologists achieved an average agreement of 76.3 percent with reference scores across 1,940 readings without AI (exams A and B), compared to 89.6 percent on exam C (with AI assistance). Accuracy improved from 66.7 percent without AI to 88.5 percent with AI for HER2 clinical categories (null, ultralow, low, positive). In 29.5 percent of readings without AI, misclassification of HER2-ultralow cases as HER2 null occurred; with AI assistance, this decreased to 4.0 percent.

"Our study provides the first multinational evidence that artificial intelligence can help close a critical diagnostic gap and open the door to new therapies like antibody-drug conjugates for a majority of patients who, until recently, had not been offered these options," lead author Marina De Brot, M.D., Ph.D., from the Camargo Cancer Center in São Paolo, Brazil, said in a statement.

Several authors disclosed ties to biopharmaceutical companies, including AstraZeneca, which funded the study.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-31 00:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords